K Van Herck
Overview
Explore the profile of K Van Herck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
266
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus J, et al.
J Viral Hepat
. 2008 Oct;
15 Suppl 2:1-15.
PMID: 18837827
For the first time a global meeting on hepatitis A virus (HAV) infection as vaccine preventable disease was organized at the end of 2007. More than 200 experts from 46...
12.
Van Herck K, Leuridan E, Van Damme P
Sex Transm Infect
. 2007 Oct;
83(6):426-32.
PMID: 17911142
Introduction: Vaccination is an important tool in hepatitis B prevention. However, several vaccine doses are required to induce long-term protection. Several at-risk groups have difficulties in adhering to the standard...
13.
Van Herck K, Leroux-Roels G, Van Damme P, Srinivasa K, Hoet B
Travel Med Infect Dis
. 2007 Apr;
5(3):171-5.
PMID: 17448944
Background: Hepatitis A and B infections are prevalent worldwide and cause significant morbidity and mortality. A combined vaccine providing dual protection against hepatitis A and B is available (Twinrix, GlaxoSmithKline...
14.
Wouters K, Leuridan E, Van Herck K, van Ardenne N, Roelofs I, Mak R, et al.
Vaccine
. 2007 Jan;
25(10):1893-900.
PMID: 17239492
Objectives: To compare the coverage for the third dose and the compliance to two hepatitis B vaccination schedules: 0,1,4 versus 0,1,6 months, in commercial sex workers (CSW) in Belgium; to...
15.
Goethaert K, Van Looveren M, Lammens C, Jansens H, Baraniak A, Gniadkowski M, et al.
Clin Microbiol Infect
. 2006 Feb;
12(1):56-62.
PMID: 16460547
This study evaluated retrospectively the efficacy of treatment with cefepime vs. a carbapenem, in combination with amikacin or ciprofloxacin, for seriously-ill patients infected with ESBL-producing Enterobacter aerogenes who were admitted...
16.
Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, et al.
Lancet
. 2003 Oct;
362(9389):1065-71.
PMID: 14522539
Hepatitis A is one of the most common vaccine-preventable infectious diseases in the world. Effective vaccines against hepatitis A have been available since 1992, and they provide long-term immunity against...
17.
Van Damme P, Leroux-Roels G, Law B, Diaz-Mitoma F, Desombere I, Collard F, et al.
J Med Virol
. 2001 Aug;
65(1):6-13.
PMID: 11505437
It is important to monitor the long-term persistence of antibodies induced by vaccination. Four cohorts were followed for their long-term immunity after vaccination with a combined hepatitis A and B...
18.
Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence
Van Herck K, Van Damme P
J Med Virol
. 2000 Dec;
63(1):1-7.
PMID: 11130881
To estimate the long-term persistence of anti-HAV antibodies, 120 (schedule 0-6) and 194 (schedule 0-12) adults were vaccinated and followed-up annually for 6 years. Shortly after the last dose, anti-HAV...
19.
Van Damme P, Van Herck K, Meheus A
Epidemiology
. 2000 Apr;
11(3):364; author reply 366.
PMID: 10784262
No abstract available.
20.
Van Herck K, Van Damme P, Collard F, Thoelen S
Scand J Gastroenterol
. 2000 Jan;
34(12):1236-40.
PMID: 10636072
Background: In this open, randomized trial the safety, reactogenicity, and immunogenicity profile of a high-dose combined hepatitis A and B candidate vaccine was compared with that of Twinrix Paediatric in...